[1]黄文薮,蔡明岳,曾昭吝,等.TACE联合125I放射性粒子植入治疗肝细胞癌门静脉癌栓[J].介入放射学杂志,2015,(06):488-493.
　HUANG Wen- sou,CAI Ming- yue,ZENG Zhao- lin,et al.Transarterial chemoembolization combined with CT- guided 125I seed implantation for the treatment of hepatocellular carcinoma associated with portal vein tumor thrombus[J].journal interventional radiology,2015,(06):488-493.
点击复制

TACE联合125I放射性粒子植入治疗肝细胞癌门静脉癌栓()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2015年06期
页码:
488-493
栏目:
肿瘤介入
出版日期:
2015-06-25

文章信息/Info

Title:
Transarterial chemoembolization combined with CT- guided 125I seed implantation for the treatment of hepatocellular carcinoma associated with portal vein tumor thrombus
作者:
黄文薮;  蔡明岳;  曾昭吝;  黄敬君;  黄明声;  单 鸿;  朱康顺
Author(s):
HUANG Wen- sou;  CAI Ming- yue;  ZENG Zhao- lin;  HUANG Jing- jun;  HUANG Ming- sheng;  SHAN Hong;  ZHU Kang- shun
Department of Radiology， Third Affiliated Hospital of Sun Yet- sen University， Interventional Radiology Institute， Sun Yat- sen University， Guangzhou， Guangdong Province 510630， China
关键词:
【关键词】 肝细胞癌;  门静脉癌栓;  近距离内照射治疗;  肝动脉化疗栓塞
文献标志码:
A
摘要:
【摘要】 目的 探讨TACE联合125I放射性粒子植入治疗肝细胞癌（HCC）门静脉癌栓（PVTT）的方法及疗效。方法 纳入TACE联合CT引导下植入125I放射性粒子治疗的HCC合并PVTT患者48例。根据PVTT部位，分为门静脉主干癌栓（A型）、门静脉一级分支癌栓（B型）和门静脉二级及以下分支癌栓（C型）。根据粒子是否植入到PVTT内，分为癌栓内直接植入法（癌栓内部植入组）和癌栓周围植入法（其粒子植入到癌栓周围1.7 cm内的肝实质或肿瘤内，癌栓周围植入组）。比较不同类型PVTT及不同植入方法的癌栓控制率（DCR）、癌栓进展时间（TTP）及患者总生存率（OS）。结果 48例患者均成功进行TACE及粒子植入治疗。A、B、C型PVTT患者，中位OS（mOS）分别为8、11.5和15个月，组间差异有统计学意义（P=0.003）；癌栓DCR分别为61.5%、70.8%和72.7%（P=0.548），肝内肿瘤DCR分别为69.2%、75.0%和81.8%（P=0.483）；癌栓中位TTP分别为4.5、8和11个月（P=0.030），肝内肿瘤中位TTP分别为5、9和9.5个月。癌栓内部植入组和癌栓周围植入组的mOS分别为10和11.5个月（P=0.239）；癌栓DCR分别为69.2%、68.2%（P=0.591），肝内肿瘤DCR分别为73.1%和77.3%（P=0.502）；癌栓中位TTP分别为7和10个月（P=0.276），肝内肿瘤中位TTP分别为8和9.5个月（P=0.089）。结论 TACE联合125I放射性粒子植入治疗HCC伴PVTT，可有效控制PVTT和肝内肿瘤进展，延长患者生存期；癌栓内直接植入法和癌栓周围植入法，对PVTT的疗效无影响。

参考文献/References:

［1］ Minagawa M, Makuuchi M. Treatment of hepatocellularcarcinoma accompanied by portalvein tumor thrombus［J］. World J Gastroen- terol, 2006, 12: 7561- 7567.
［2］ Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials［J］. Hepatology, 1999, 29: 62- 67.
［3］ Bruix J, Sherman M， Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellulacarcinoma［J］. Hepatology, 2005, 42: 1208- 1236.
［4］ Tazawa J, Maeda M, Sakai Y, et al. Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement［J］. J Gastroenterol Hepatol, 2001, 16: 660- 665.
［5］ Zhu K, Chen J, Lai L, et al. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembo- lization combined with sorafenib: a retrospective controlled study［J］. Radiology, 2014, 272: 284- 293.
［6］ Lencioni R, Llovet JR. Modified RECIST （mRECIST） assessment for hepatocellular carcinoma ［J］. Semin Liver Dis, 2010, 30: 52- 60.
［7］ Zeng ZC, Fan J, Tang ZY, et al. A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus［J］. Int J Radiat Oncol Biol Phys, 2005, 61: 432- 443.
［8］ 刘 健， 张福君， 吴沛宏， 等． CT导向下125Ⅰ粒子植入治疗肝门区肝癌［J］． 介入放射学杂志， 2005， 14： 606- 609．
［9］ 翁志成， 杨维竹， 江 娜， 等． CT引导下125Ⅰ放射性粒子植入治疗肝癌门静脉癌栓的疗效评价［J］． 介入放射学杂志， 2010， 19： 535- 539．
［10］ Chung GE, Lee JH, Kim HY, et al. Transarterial chemoembo lization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival ［J］. Radiology, 2011, 258: 627- 634.
［11］ Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study［J］. Ann Surg Oncol, 2011, 18: 413- 420.
［12］ Georgiades CS, Hong K. D’angelo M, et al. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis［J］. J Vasc Interv Radiol, 2005, 16: 1653- 1659.
［13］ Shi J, Lai EH, Li N, et al. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus［J］. Ann Surg Oncol, 2010, 17: 2073- 2080.
［14］ Niu ZJ, Ma YL, Kang P, et al. Transarterial chemoembolization compared with conservative treatment for advanced hepatoce llular carcinoma with portal vein tumor thrombus: using a new classification［J］. Med Oncol, 2012, 29: 2992- 2997.

相似文献/References:

[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良ＲＥＣＩＳＴ标准更可靠[J].介入放射学杂志,2012,(03):177.
　. Ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ ｃｒｉｔｅｒｉｏｎ ｏｆ ｉｎｏｐｅｒａｂｌｅ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ｍｏｄｉｆｉｅｄ ＲＥＣＩＳＴ ａｓ ａ ｍｏｒｅ ｒｅｌｉａｂｌｅ ｓｔａｎｄａｒｄ[J].journal interventional radiology,2012,(06):177.
[2].关于召开“全国肝癌介入治疗研讨会”的通知[J].介入放射学杂志,1995,(04):200.
[3]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
　.Ｔｈｅ ｔｒａｎｓｆｏｒｍａｔｉｏｎ ｐａｔｔｅｒｎ ｏｆ ｓｅｒｕｍ аｆｅｔｏｐｒｏｔｅｉｎ ａｆｔｅｒ ｔｒａｎｓｃａｔｈｅｔｅｒ ａｒｔｅｒｉａｌ ｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａ： ｉｔｓ ｃｌｉｎｉｃａｌ ｓｉｇｎｉｆｉｃａｎｃｅ [J].journal interventional radiology,2012,(06):333.
[4]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
　,,et al.Ｔｈｅ ｆａｃｔｏｒｓ ｒｅｌａｔｅｄ ｔｏ ｔｈｅ ｆｏｒｍａｔｉｏｎ ｏｆ ａｒｔｅｒｉｏｐｏｒｔａｌ ｓｈｕｎｔｉｎｇ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ [J].journal interventional radiology,2012,(06):206.
[5]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ；[J].介入放射学杂志,2012,(06):469.
　SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(06):469.
[6]李晓峰,钱国军,张 磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
　LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(06):974.
[7]张　　　磊,陆骊工,李　　　勇,等.门静脉支架联合肝动脉化疗栓塞治疗肝癌伴门静脉癌栓的临床研究[J].介入放射学杂志,2011,(12):968.
　ZHANG Lei,LU Li-gong,LI Yong,et al.Portal vein stent placement combined with TACE for the treatment of hepatocellular carcinoma associated with tumor thrombus in portal vein[J].journal interventional radiology,2011,(06):968.
[8]彭辽河,胡晓燕,李 杰,等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值[J].介入放射学杂志,2012,(08):636.
　PENG Liao- he,HU Xiao- yan,LI Jie,et al. Clinical application of 18F- FDG PET/CT imaging in detecting residual lesions or recurrence foci of hepatocellular carcinoma after TACE treatment[J].journal interventional radiology,2012,(06):636.
[9]陆小华,朱小庆,茅国新.肝细胞癌相关单核苷酸多态性的研究进展[J].介入放射学杂志,2013,(06):520.
　LU Xiao? hua,ZHU Xiao? qing,MAO Guo? xin.. Hepatocellular carcinoma?蛳 related single nucleotide polymorphisms： recent advances in research[J].journal interventional radiology,2013,(06):520.
[10]李海伟,刘 静,李 森.125I粒子植入与伽玛刀治疗门脉癌栓的疗效对比[J].介入放射学杂志,2014,(08):702.
　LI Hai wei,LIU Jing,LI Sen..125Iodine seed implantation and gamma knife for the treatment of portal vein tumor thrombosis in hepatocellular carcinoma： comparison of therapeutic efficacy[J].journal interventional radiology,2014,(06):702.
[11]陈 嵩,吴志强,庄文权,等.经肝动脉栓塞术联合FOLFOX4方案持续动脉灌注化疗治疗肝细胞癌合并门静脉癌栓15例近期临床疗效评价[J].介入放射学杂志,2019,28(04):328.
　CHEN Song,WU Zhiqiang,ZHUANG Wenquan,et al.TAE combined with continuous hepatic artery infusion chemotherapy with FOLFOX4 scheme for HCC associated with PVTT： evaluation of its short- term efficacy in 15 patients[J].journal interventional radiology,2019,28(06):328.
[12]王万胜,王 晨,沈 健,等.复合125I粒子植入技术联合TACE治疗肝癌合并门静脉癌栓[J].介入放射学杂志,2021,30(07):680.
　WANG Wansheng,WANG Chen,SHEN Jian,et al.Complex 125I seed implantation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma complicated by portal vein tumor thrombus[J].journal interventional radiology,2021,30(06):680.
[13]刘 琦,张 颖,张精文,等.HAIC联合靶向和免疫治疗晚期肝癌伴门脉主干癌栓的研究[J].介入放射学杂志,2024,33(07):738.
　LIU Qi,ZHANG Ying,ZHANG Jingwen,et al.HAIC combined with targeted therapy and immunotherapy for advanced liver cancer complicated by main portal vein tumor thrombus： a clinical study[J].journal interventional radiology,2024,33(06):738.

备注/Memo

备注/Memo:
（收稿日期：２０１4 -11 -17）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2015-06-24